Should clozapine continue to be restricted to third-line status for schizophrenia?: A decision-analytic model

Journal of Mental Health Policy and Economics

Volumn 7, Issue 2, 2004, Pages 77-85

  Wang, Philip S ^a   Ganz, David A ^a   Benner, Joshua S ^a   Glynn, Robert J ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MALE; OUTCOMES RESEARCH; PROBABILITY; PSYCHOSIS; QUALITY ADJUSTED LIFE YEAR; SCHIZOPHRENIA; SENSITIVITY ANALYSIS;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DECISION SUPPORT SYSTEMS, CLINICAL; HUMANS; MARKOV CHAINS; OUTCOME ASSESSMENT (HEALTH CARE); PROBABILITY; QUALITY-ADJUSTED LIFE YEARS; SCHIZOPHRENIA; UNITED STATES;

EID: 2942739132     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Lehman AF, Steinwachs DM. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bull 1998; 24: 1-10.
2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Washington, D.C.: American Psychiatric Association, 1997.
3. Physicians' Desk Reference. 54th Edition. Medical Economics Company, Montvale, NJ. 2000.
4. Griffith RW, Saameli J. Clozapine and agranulocytosis. Lancet 1975; 2: 657.
5. Alvir JMJ, Lieberman JA, Safferman AZ, Schwimmer JL, Schaaf JA. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-167.
6. Meltzer HY, Cola PA. The pharmacoeconomics of clozapine: a review. J Clin Psychiatry 1994; 55:161-165.
7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
8. Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999; 156: 990-999.
9. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer RM. Atypical and conventional antipsychotic drugs in treatment-naïve first episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine. Neuropsychopharmacology 2003; 28: 995-1003.
10. Honigfeld G, Arellano F, Sethi J, Bianchini A, Schein J. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(suppl 3): 3-7.
11. Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. Br J Psychiatry 1991; 158: 503-510.
12. Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-677.
13. Meltzer HY, Fatemi H. Suicide in schizophrenia: the effect of clozapine. Clin Neuropharmacol 1995; 18: S18-S24.
14. Meltzer HY, Okayli G. Reduction bf suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-190.
15. Meltzer HY, Alphs, L, Green AI, Altamura A, Anand R, Bertoldi A, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60: 82-91.
16. Drug Topics Red Book. Medical Economics Company, Montvale, NJ. 1999.
17. Meltzer HY. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry. 1998; 59 (Suppl 3): 15-20.
18. Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med 1997; 337: 809-815.
19. Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch Gen Psychiatry 1999; 56: 565-572.
20. Rosenheck R, Cramer J, Xu W, Grabowski J, Douyon R. Thomas J, Henderson W, Charney D. Multiple outcome assessment in a study of the cost-effectiveness of clozapine in the treatment of refractory schizophrenia. Health Serv Res 1998; 33: 1237-1261.
21. Meltzer HY, Cola P, Way L, Thompson PA, Bastani B, Davies MA, Snitz B. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150: 1630-1638.
22. Honigfeld G, Patin J. A two-year clinical and economic follow-up of patients on clozapine. Hosp Commun Psychiatry 1990; 41: 882-885.
23. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment- resistant schizophrenic patients. Hosp Commun Psychiatry 1990; 41: 850-854.
24. Jonsson D, Wålinder J. Cost-effectiveness of clozapine treatment in therapy-refractory schizophrenia. Acta Psychiatr Scand 1995; 92: 199-201.
25. Glennie JL. Pharmacoeconomic evaluations of clozapine in treatment-resistant schizophrenia and risperidone in chronic schizophrenia. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment (CCOHTA), July 1997.
26. Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Managed Care 1998; 4: 345-355.
27. Davies LM, Drummond MF. Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162: 38-42.
28. Oh PI, Iskedjian M, Addis A, Lanctot K, Einarson TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001; 8: 199-206.
29. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987-994.
30. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia. Schizophr Bull 1997; 23: 663-674.
31. Wang PS, West JC, Tanielian T, Pincus HA. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000; 26: 451-457.
32. Azorin JM, Spiegel R, Remington G, Vanelle JM, Pere JJ, Giguere M, Bourdeix I. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry 2001; 158: 1305-1313.
33. Reicher A, Maurer K, Loffler W, Fatkenheuer B, An Der Heiden W, Munk-Jorgensen P, Stromgren E, Hafner H. 1991. Gender differences in the age of onset and course of schizophrenic disorders. In: Hafner H, Gattaz WF, eds. Search for the causes of schizophrenia. Berlin: Springer, pp. 14-33.
34. Bromet EJ, Dew MA, Eaton WW. 2002. Epidemiology of psychosis with special reference to schizophrenia. In: Tsuang MT, Tohen M, eds. Textbook in psychiatric epidemiology. New York: John Wiley, pp. 365-387.
35. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338.
36. National Center for Health Statistics. Vital statistics of the United States, 1995. Volume II, Mortality, Part A, Section 6: life tables. DHHS Publication No (PHS) 98-1147. Hyattsville, MD: US Dept. HHS, 1998.
37. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-245.
38. Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacol Bull 1986; 22: 254-258.
39. Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 189-192.
40. Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Internat Clin Psychopharmacol 1996; 11: 101-108.
41. Weeks JC, Tierney MR, Weinstein MC. Cost-effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991; 325: 81-86.
42. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
43. Marder SR. Antipsychotic medications. In: Schatzberg AF, Nemeroff CB, eds. Textbook of psychopharmacology, 2nd edition. American Psychiatric Press, Wash., D.C. 1998.
44. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-429.
45. Zhang M, Owen RR, Pope SK, Smith GR. Cost-effectiveness of clozapine monitoring after the first 6 months. Arch Gen Psychiatry 1996; 53: 954-958.
46. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in revolving door schizophrenic patients. J Clin Psychiatry 1996; 57: 337-345.
47. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation: a practical approach. Med Decis Making 1985; 5: 157-177.
48. Graham JD, Corso PS, Morris JM, Segui-Gomez M, Weinstein MC. Evaluating the cost-effectiveness of clinical and public health measures. Ann Rev Pub Health. 1998; 19: 125-152.
49. Sachdev P. The epidemiology of drug-induced akathisia: Part II. Chronic, tardive, and withdrawal akathisias. Schizophr Bull. 1995; 21: 451-461.
50. Sernyak M, Desai R, Stolar M, Rosenheck R. Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931-937.
51. Hughes DA, Bagust A, Haycox A, Walley T. The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature. Health Economics 2001; 10: 601-615.
52. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34: 702-712.
53. Palmer CS, Revicki DA, Halpern MT, Hatziandreu EJ. The cost of suicide and suicide attempts in the United States. Clin Neuropharmacol 1995; 18: S25-S33.
54. Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K. Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 1995; 15 (1 suppl 1): 45S-51S.
55. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry 1998; 155: 499-504.
56. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Br Med J 2000; 321: 1371-1376.